Sacituzumab Tirumotecan Meets Overall Survival Endpoint

Company Merck; Sichuan Kelun-Biotech Event Type Phase 3 topline (TroFuse-015) Modality Antibody-drug conjugate Asset Sacituzumab tirumotecan (sac-TMT) Target TROP2 Disease Area Third-line or later gastroesophageal adenocarcinoma Summary Merck reported November 20 that global Phase 3 TroFuse-015 met its primary overall-survival endpoint in third-line or later…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *